Diseases & Conditions
Grants & Contracts
News & Events
The core services group at the Integrated Research Facility at Fort Detrick (IRF Frederick) provides cell culture, hematology, hemostasis, clinical chemistry, microbiology, and molecular virology support for monitoring animals in infectious disease studies.
The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) program supports the evaluation of early-stage diagnostics and novel diagnostic strategies for TB, in TB endemic countries to address an urgent need for improved tuberculosis (TB) diagnostics.
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.
The Immcantation framework is developed as a start-to-finish analytical ecosystem for large-scale characterization of B cell receptor (BCR) and T cell receptor (TCR) repertoires from high-throughput adaptive immune receptor repertoire sequencing (AIRR-seq) datasets.
ImmPort is a Web portal that contains data from NIAID-funded immunology studies, including basic research and clinical trials. The portal provides online tools that allow users to analyze the data and visualize the results.
The Microbicide Trials Network (MTN) is a NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. The MTN accepts concepts for new protocols, ancillary study proposals, secondary data analysis requests, and dataset requests.
The NIAID Centralized Sequencing Program serves as a genomics resource for NIAID human subjects research studies to help address interrelated challenges in clinical care and NIAID Intramural research. Any NIAID participant is eligible to receive genome sequencing and associated services through this protocol.
Researchers involved with the NIAID Clinical Genomics Program study many diseases of the immune system that are rare and not well understood but often shed light on basic immune function and more common immune disorders.
The primary objective of the Clinical Studies Support Team (CSST) is to develop and foster overseas relationships through the support of research studies and clinical trials.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo
This Gene Set Enrichment-type test designed for analysis of microarray and RNASeq data is designed to provide a faster, more accurate, and easier to understand test for gene expression studies. QuSAGE extends previous methods with a complete probability density function (PDF).
Current methods for monitoring HIV-infected patients on antiretroviral therapy are expensive and technologically complex, making it difficult for use in resource-limited countries around the world.
The NIAID TB Portals Program is a multi-national collaboration for tuberculosis (TB) data sharing and analysis to advance TB research.
The Throughput Ranking by Iterative Analysis of Genomic Enrichment (TRIAGE) platform is designed to facilitate prediction, analysis, and hypothesis generation from High-throughput genomic studies such as those done by CRISPR, RNAseq, proteomic, and clinical sequencing studies.